Tempest Total Current Assets from 2010 to 2026
| TPST Stock | USD 2.40 0.17 7.62% |
Total Current Assets | First Reported 2012-06-30 | Previous Quarter 15.1 M | Current Value 8.1 M | Quarterly Volatility 39.1 M |
Check Tempest Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tempest Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 37.9 M, Research Development of 19 M or Total Operating Expenses of 37.2 M, as well as many indicators such as Price To Sales Ratio of 1.36, Dividend Yield of 0.0 or PTB Ratio of 14.96. Tempest financial statements analysis is a perfect complement when working with Tempest Therapeutics Valuation or Volatility modules.
Tempest | Total Current Assets | Build AI portfolio with Tempest Stock |
The evolution of Total Current Assets for Tempest Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Tempest Therapeutics compares to historical norms and industry peers.
Latest Tempest Therapeutics' Total Current Assets Growth Pattern
Below is the plot of the Total Current Assets of Tempest Therapeutics over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Tempest Therapeutics' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tempest Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Assets | 10 Years Trend |
|
Total Current Assets |
| Timeline |
Tempest Total Current Assets Regression Statistics
| Arithmetic Mean | 49,052,025 | |
| Geometric Mean | 35,564,817 | |
| Coefficient Of Variation | 72.77 | |
| Mean Deviation | 27,927,982 | |
| Median | 40,363,000 | |
| Standard Deviation | 35,693,059 | |
| Sample Variance | 1274T | |
| Range | 125.3M | |
| R-Value | 0 | |
| Mean Square Error | 1358.9T | |
| R-Squared | 0.00000998 | |
| Significance | 0.99 | |
| Slope | 22,333 | |
| Total Sum of Squares | 20383.9T |
Tempest Total Current Assets History
About Tempest Therapeutics Financial Statements
Tempest Therapeutics shareholders use historical fundamental indicators, such as Total Current Assets, to determine how well the company is positioned to perform in the future. Although Tempest Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Tempest Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tempest Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Assets | 28.3 M | 43.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.